Benzinga · Aug 10, 2026
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $42 to $46.
RO
NASDAQ · ROIV
Roivant Sciences Ltd.
Healthcare · Biotechnology
$37.37
Up+$1.13 (+3.12%)
Updated Aug 19, 2026, 8:18 AM
SID Score
7.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 14.83B
- P/E ratio
- -38.83
- Dividend yield
- 0.00%
- 52-week range
- $11.60 – $37.46
- Volume
- 6.41M
- Avg. volume
- 8.16M
Price performance
ROIV price history
1M range · 21 trading sessions · Daily adjusted prices
ROIV closed at $37.37 after 21 trading sessions, up 6.89% for the selected period.
- Last close
- $37.37
- Period change
- +6.89%
- Period low
- $32.87
- Period high
- $37.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $35.91 | $37.46 | $35.86 | $37.37 | 6.41M |
| Aug 17, 2026 | $36.22 | $37.19 | $35.65 | $36.24 | 7.73M |
| Aug 14, 2026 | $36.135 | $36.49 | $35.87 | $36.20 | 4.53M |
| Aug 13, 2026 | $36.70 | $36.70 | $35.78 | $36.28 | 6.03M |
| Aug 12, 2026 | $35.22 | $36.50 | $35.22 | $36.16 | 4.99M |
| Aug 11, 2026 | $36.00 | $36.00 | $34.56 | $35.25 | 5.84M |
| Aug 10, 2026 | $36.05 | $36.78 | $35.68 | $35.78 | 7.94M |
| Aug 7, 2026 | $35.88 | $36.44 | $35.62 | $36.34 | 6.74M |
| Aug 6, 2026 | $33.11 | $35.37 | $33.11 | $35.12 | 8.25M |
| Aug 5, 2026 | $34.89 | $35.56 | $34.35 | $34.60 | 5.86M |
| Aug 4, 2026 | $33.74 | $34.70 | $33.45 | $34.59 | 5.88M |
| Aug 3, 2026 | $33.225 | $33.43 | $32.47 | $33.32 | 5.99M |
| Jul 31, 2026 | $34.275 | $34.50 | $33.54 | $33.91 | 5.4M |
| Jul 30, 2026 | $33.39 | $34.54 | $33.01 | $34.52 | 4.56M |
| Jul 29, 2026 | $33.85 | $34.30 | $32.83 | $32.87 | 4.82M |
| Jul 28, 2026 | $34.62 | $34.83 | $33.50 | $33.84 | 4.4M |
| Jul 27, 2026 | $35.13 | $35.58 | $34.59 | $34.72 | 4.27M |
| Jul 24, 2026 | $35.23 | $35.59 | $34.795 | $35.01 | 4.04M |
| Jul 23, 2026 | $34.46 | $35.695 | $34.14 | $35.10 | 4.25M |
| Jul 22, 2026 | $34.65 | $35.13 | $34.55 | $34.91 | 3.4M |
| Jul 21, 2026 | $34.14 | $35.24 | $34.02 | $34.96 | 4.73M |
Latest ROIV news
The latest Smart Investors Daily articles mentioning ROIV.
Stock researchCompany · Overview
ROIV research
Overview
Company profile and research snapshot.
Company profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | Guggenheim | Buy | — |
| May 21, 2026 | Citigroup | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 9, 2026
Is Roivant Sciences’ (ROIV) Cost Discipline Offsetting Slower Revenue Enough to Refresh Its Story?
Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per share highlights Roivant’s ongoing effort to manage costs while progressing its inflammation and immunology portfolio. We’ll now examine how this combination of reduced sales and a smaller quarterly net loss could...
Yahoo · Aug 9, 2026
Is Roivant Sciences (ROIV) Overvalued On First Quarter Results?
Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the period ended June 30, 2026. Sales were US$1.44 million, while the company reported a net loss of US$189.84 million. The loss from continuing operations translated into a basic loss per share of US$0.26. Investors are now weighing how these figures, together with the updated loss profile, fit into the broader story for this clinical stage...
SeekingAlpha · Aug 8, 2026
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma. Check out why ROIV stock is a buy.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
